Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237683 | 0.84 | GAA (0.63) | LMNAPOLBGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL403360 | 0.81 | HDAC3 (0.49) | LMNAPOLBRAB9ANPC1HDAC6 | |
| SCHEMBL6538970 | 0.79 | NR1H4 (0.51) | LMNAPOLBGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL8374747 | 0.75 | GFER (0.55) | LMNAGAASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL3993028 | 0.75 | LMNA (0.59) | LMNAPOLBGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL10545735 | 0.74 | KDM4E (0.59) | LMNAPOLBSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL8372261 | 0.74 | CYP1A2 (0.58) | LMNAPOLBGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL8374746 | 0.74 | NPC1 (0.51) | LMNAPOLBGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL7272796 | 0.73 | GPR139 (0.60) | LMNAPOLBGAASMN1; SMN2RAB9A | |
| SCHEMBL3205192 | 0.73 | MAPT (0.61) | LMNASMN1; SMN2ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120020881-A1 | Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020881-A1 | Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes | KIT, STS, TST | LMNA 3824/4885POLB 2263/4885GAA 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.